参考文献/References:
[1] 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志,2018(4):196-225.
[2] 徐俊波黄刚蔡琳等. 2019 ESC-HFA射血分数保留性心力衰竭诊断共识的解读[J]. 心血管病学进展,2019,40(9):1193-1195+1211.
[3] Eichhorn LWeisheit CK,Gestrich C,et al. A closed-chest model to induce transverse aortic constriction in mice[J]. J Vis Exp,2018,(134):e57397.
[4] Bosch L,de Haan JJ,Bastemeijer M,et al. The transverse aortic constriction heart failure animal model:a systematic review and meta-analysis[J]. Heart Fail Rev,2021,26(6):1515-1524.
[5] Ukita R,Tipograf Y,Tumen A,et al. Left pulmonary artery ligation and chronic pulmonary artery banding model for inducing right ventricular-pulmonary hypertension in sheep[J]. ASAIO J,2021,67(1):e44-e48.
[6] Liu J,Ji XX,Fu Y,et al. Early passive leg movement prevents against the development of heart failure with preserved ejection fraction in rats[J]. Front Cardiovasc Med,2021,8:655009.
[7] Abassi Z,Goltsman I,Karram T,et al. Aortocaval fistula in rat:a unique model of volume-overload congestive heart failure and cardiac hypertrophy[J]. J Biomed Biotechnol,2011,2011:729497.
[8] Yamamoto K,Protack CD,Tsuneki M,et al. The mouse aortocaval fistula recapitulates human arteriovenous fistula maturation[J]. Am J Physiol Heart Circ Physiol,2013,305(12):H1718-H1725.
[9] 陈会花章忱吕嵘. 舒张性心力衰竭实验动物模的研究进展[J]. 中国实验动物学报,2017,25(3):336-339.
[10] Watanabe SBikou O,Hajjar RJ,et al. Swine model of mitral regurgitation induced heart failure[J]. Methods Mol Biol,2018,1816:327-335.
[11] Li B,Cui Y,Zhang D,et al. The characteristics of a porcine mitral regurgitation model[J]. Exp Anim,2018,67(4):463-477.
[12] Chinyere IR,Moukabary T,Hutchinson MD,et al. Progression of infarct-mediated arrhythmogenesis in a rodent model of heart failure[J]. Am J Physiol Heart Circ Physiol,2021,320(1):H108-H116.
[13] Abukar Y,Lever N,Pachen M,et al. Impaired baroreflex function in an ovine model of chronic heart failure induced by multiple coronary microembolizations[J]. Front Physiol,2019,10:1420.
[14] Janssen PML,Elnakish MT. Modeling heart failure in animal models for novel drug discovery and development[J]. Expert Opin Drug Discov,2019,14(4):355-363.
[15] Powers JC,Recchia F. Canine model of pacing-induced heart failure[J]. Methods Mol Biol. 2018,1816:309-325.
[16] 徐俊波黄刚蔡琳等. 肿瘤心血管病学的循证临床实践[J]. 心血管病学进展,2020,41(5):468-471.
[17] Lodi MPriksz D,Fulop GA,et al. Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy[J]. J Transl Med,2019,17(1):229.
[18] Nichtova Z,Novotova M,Kralova E,et al. Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol[J]. Gen Physiol Biophys,2012,31(2):141-151.
[19] Hornyik T,Rieder M,Castiglione A,et al. Transgenic rabbit models for cardiac disease research[J]. Br J Pharmacol,2021 Apr 6. DOI: 10.1111/bph.15484.
[20] Jiang M,Hu H,Zhao K,et al. The G4 resolvase RHAU modulates mRNA translation and stability to sustain postnatal heart function and regeneration[J]. ?J Biol Chem,2021,296:100080.
[21] Molinari F,Malara N,Mollace V,et al. Animal models of cardiac cachexia[J]. Int J Cardiol,2016,219:105-110.
[22] Camara AKS,Stowe DF,O-Uchi J,et al. Editorial:genetic modification of cardiac tissue[J]. Front Cardiovasc Med,2019,6:93.
[23] Lindsey ML,Bolli R,Canty JM,et al. Guidelines for experimental models of myocardial ischemia and infarction[J]. Am J Physiol Heart Circ Physiol,2018,314(4):H812-H838.
[24] McKenna WJ,Judge DP. Epidemiology of the inherited cardiomyopathies[J]. Nat Rev Cardiol,2021,18(1):22-36.
[25] Sorrentino A,Michel T. Redox a la carte:novel chemogenetic models of heart failure[J]. Br J Pharmacol,2020,177(14):3162-3167.
[26] Seferovic PM,Petrie MC,Filippatos GS,et al. Type 2 diabetes mellitus and heart failure:a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail,2018,20(5):853-872.
[27] Al-Awar A,Kupai K,Veszelka M,et al. Experimental diabetes mellitus in different animal models[J]. J Diabetes Res,2016,2016:9051426.
[28] Riehle C,Bauersachs J. Of mice and men:models and mechanisms of diabetic cardiomyopathy[J]. Basic Res Cardiol,2018,114(1):2.
[29] Oana S,Ilkka H,Matthijs VK,et al. Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction,oxidative stress and myocardial stiffening[J]. Cardiovasc Res,2018,114(7):954-964.
[30] Horvath O,Ordog K,Bruszt K,et al. BGP-15 protects against heart failure by enhanced mitochondrial biogenesis and decreased fibrotic remodelling in spontaneously hypertensive rats[J]. Oxid Med Cell Longev,2021,2021:1250858.
[31] Sheng C,Zhang C,Li Y,et al. Effect of β-casomorphin-7 on myocardial hypertrophy in hyperthyroidism-induced cardiomyopathy[J]. Eur Rev Med Pharmacol Sci,2020,24(11):6380-6389.
[32] Del Buono MG,Iannaccone G,Scacciavillani R,et al. Heart failure with preserved ejection fraction diagnosis and treatment:An updated review of the evidence[J]. Prog Cardiovasc Dis,2020,63(5):570-584.
[33] Schwarzl M,Hamdani N,Seiler S,et al. A porcine model of hypertensive cardiomyopathy:implications for heart failure with preserved ejection fraction[J]. Am J Physiol Heart Circ Physiol,2015,309(9):H1407-H1418.
[34] Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200.
[35] Noll NA,Lal H,Merryman WD. Mouse models of heart failure with preserved or reduced ejection fraction[J]. Am J Pathol,2020,190(8):1596-1608.
[36] Abraham WT,Kuck KH,Goldsmith RL,et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation[J]. JACC Heart Fail,2018,6(10):874-883.
[37] Sharma K,Premchand RK,Mittal S,et al. Long-term follow-up of patients with heart failure and reduced ejection fraction receiving autonomic regulation therapy in the ANTHEM-HF pilot study[J]. Int J Cardiol,2021,323:175-178.
[38] Monreal G,Sherwood LC,Sobieski MA,et al. Large animal models for left ventricular assist device research and development[J]. ASAIO J,2014,60(1):2-8.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(12):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(12):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(12):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(12):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(12):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(12):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]